Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Fuji
Novartis
Express Scripts
Colorcon
Moodys
QuintilesIMS
Queensland Health
Fish and Richardson
Merck

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,456,168

« Back to Dashboard

Which drugs does patent 7,456,168 protect, and when does it expire?

Patent 7,456,168 protects IBRANCE and is included in one NDA.

This patent has sixty-four patent family members in forty-seven countries.
Summary for Patent: 7,456,168
Title:2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4). ##STR00001##
Inventor(s): Barvian; Mark (Ann Arbor, MI), Booth; Richard John (Ann Arbor, MI), Quin, III; John (Ann Arbor, MI), Repine; Joseph Thomas (Ann Arbor, MI), Sheehan; Derek J. (Dexter, MI), Toogood; Peter Laurence (Ann Arbor, MI), Vanderwel; Scott Norman (Ann Arbor, MI), Zhou; Hairong (Ann Arbor, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:11/734,200
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,456,168

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer Inc IBRANCE palbociclib CAPSULE;ORAL 207103-001 Feb 3, 2015 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Inc IBRANCE palbociclib CAPSULE;ORAL 207103-002 Feb 3, 2015 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Inc IBRANCE palbociclib CAPSULE;ORAL 207103-003 Feb 3, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,456,168

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,936,612 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones ➤ Subscribe
7,208,489 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,456,168

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 102295643 ➤ Subscribe
Colombia 5700765 ➤ Subscribe
Costa Rica 20120129 ➤ Subscribe
Germany 60303009 ➤ Subscribe
Denmark 1470124 ➤ Subscribe
Dominican Republic P2003000561 ➤ Subscribe
Eurasian Patent Organization 200400860 ➤ Subscribe
Eurasian Patent Organization 007395 ➤ Subscribe
Ecuador SP105201 ➤ Subscribe
European Patent Office 1470124 ➤ Subscribe 300863 Netherlands ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cantor Fitzgerald
Healthtrust
Dow
Baxter
Fuji
Chinese Patent Office
Harvard Business School
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot